THE WIRE · № 57258
New Phase 3b data show Lilly's EBGLYSS (lebrikizumab-lbkz) delivered significant and rapid improvements in skin clearance, itch, pain, and patient satisfaction in people with moderate-to-severe hand and foot atopic dermatitis
01 THE MACHINE READ
WHY IT MATTERS.
Phase 3b data show EBGLYSS met its primary endpoint in hand and foot atopic dermatitis, supporting label expansion.
Supports broader EBGLYSS use in difficult sites
Regulatory filing and approval decisions
Safety or reimbursement hurdles could limit uptake
FULL DISPATCH
EBGLYSS monotherapy met its primary endpoint with more than half of patients achieving clear or almost clear skin on their hands and feet (HF-IGA 0/1) by Week 16, with significant skin clearance as early as one month EBGLYSS delivered significant itch and pain relief, with significant...
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
HealthPartners and Essentia Health Propose Major Merger2026-09-30 12:56 UTC
Masimo Wins Two OCTANE High Tech Awards - Company Recognized for 'Deal of the Year' and 'Best Technology Leadership Team'2026-09-30 13:05 UTC
Union, governor’s office strike deal on state employee healthcare costs2026-09-29 22:54 UTC
CytoSorbents Announces New Data Presentations at Upcoming International Conferences in Cardiac Surgery and Critical Care2026-09-30 11:00 UTC
Citi tells investors it’s time to sell Moderna after 600%-plus stock gains2026-09-30 11:12 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.